Maintenance therapy with olaparib or selumetinib plus durvalumab (S+D) according to genetic profile of metastatic pancreatic adenocarcinoma (m-PDAC) controlled with modified FOLFIRINOX (mFFX): A phase II randomized MAZEPPA GERCOR D19-02 PRODIGE-72 study
ANNÉE
2024
AUTEURS
Hammel P, Ben Abdelghani M, Roth G, Ulusakarya A, Ghiringhelli F, Toullec C, Borg C, Hentic Dhome O, Trouilloud I,Dahan L, Hiret S, Bouche O, Rinaldi Y, Blanc JF, De La Fouchardiere C, Neuzillet C, Kamal M, Falcoz A, Turpin A, Guimbaud R
CONGRÈS/REVUE
ASCO GI
ÉTUDE
Localisation
LIEN PUBLICATIONS ASSOCIÉES